Lake Street analyst Chad Messer lowered the firm’s price target on Oncolytics (ONCY) to $5 from $7 and keeps a Buy rating on the shares after the company reported FY25 results and announced it has scheduled a Type C meeting with the FDA for April 16 to align on the design of a single-arm pivotal study for pelareorep in squamous cell anal carcinoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONCY:
- Oncolytics Biotech Establishes $75 Million ATM Offering
- Oncolytics Plans FDA Meeting for Pelareorep SCAC Study
- Oncolytics schedules FDA meeting for pelareorep registrational path
- Oncolytics Biotech Completes Domestication to Nevada with New Governance
- Oncolytics completes domicile change to the U.S.